{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_references_url in Reference URL (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03782155: Phase 4 Interventional Unknown status Wound Healing
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Beta-Hydroxyisovaleric acid (also known as 3-hydroxyisovaleric acid or 3HIA) is a normal human metabolite excreted in the urine. It is a byproduct of the leucine degradation pathway. Beta-Hydroxyisovaleric acid serves as a sensitive indicator of marginal biotin deficiency in humans. The variability of the proportion of leucine catabolites excreted as 3HIA suggests substantial population heterogeneity in the metabolic capacity of the 3HIA-carnitine detoxification pathway. In addition, was shown that in type II diabetic patients the catabolism of leucine was accelerated even in the absence of ketosis and that the urinary beta-hydroxyisovaleric acid concentration was a useful marker of short-term metabolic control in these patients.
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
US Approved Rx
(2014)
Source:
BLA125499
(2014)
Source URL:
First approved in 2014
Source:
BLA125499
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03654508: Not Applicable Interventional Completed Asthma in Children
(2018)
Source URL:
Class:
PROTEIN